Search by Drug Name or NDC

NDC 00069-1751-30 Talzenna 0.75 mg/1 Details

Talzenna 0.75 mg/1

Talzenna is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is TALAZOPARIB TOSYLATE.

MedlinePlus Drug Summary

Talazoparib is used to treat certain types of breast cancer that has spread within the breast or to other areas of the body. Talazoparib is in a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by stopping or slowing the growth of cancer cells.

Related Packages: 00069-1751-30
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Talazoparib

Product Information

NDC	00069-1751
Product ID	0069-1751_207b4971-3031-45d7-b6a4-dfe66b37650c
Associated GPIs	21535580400118
GCN Sequence Number	083085
GCN Sequence Number Description	talazoparib tosylate CAPSULE 0.75 MG ORAL
HIC3	V1Q
HIC3 Description	ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS
GCN	51934
HICL Sequence Number	045368
HICL Sequence Number Description	TALAZOPARIB TOSYLATE
Brand/Generic	Brand
Proprietary Name	Talzenna
Proprietary Name Suffix	n/a
Non-Proprietary Name	talazoparib
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	CAPSULE
Route	ORAL
Active Ingredient Strength	0.75
Active Ingredient Units	mg/1
Substance Name	TALAZOPARIB TOSYLATE
Labeler Name	Pfizer Laboratories Div Pfizer Inc
Pharmaceutical Class	Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
DEA Schedule	n/a
Marketing Category	NDA
Application Number	NDA211651
Listing Certified Through	2024-12-31

Package

NDC 00069-1751-30 (00069175130)

Pricing Information	N/A
NDC Package Code	0069-1751-30
Billing NDC	00069175130
Package	1 BOTTLE in 1 CARTON (0069-1751-30) / 30 CAPSULE in 1 BOTTLE
Marketing Start Date	2022-01-31
NDC Exclude Flag	N